RARA and hematologic disorder: The authors speculated that the upregulation of snoRNA expression was not restricted to PML-RARα mutation, but RARα plays a crucial role.15 Additional research identified snoRNA expression signatures in other hematological malignancies, such as chronic lymphocytic leukemia (CLL) and pre-B-ALL.16,17 These studies identified characteristic snoRNA expression patterns in different types of leukemia, offering theoretical evidence for clinical application of snoRNAs in disease diagnosis and prognosis.